Susquehanna International Group, LLP Kiniksa Pharmaceuticals, Ltd. Call Options Transaction History

Susquehanna International Group, LLP

15 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 07, 2024	BUY	$17.63 - $21.74 $696,385 - $858,729	39,500 Added 42.8%	131,800 $2.6 Million
Q4 2023 Feb 14, 2024	BUY	$14.37 - $19.07 $698,382 - $926,802	48,600 Added 111.21%	92,300 $1.62 Million
Q3 2023 Nov 14, 2023	BUY	$13.62 - $20.2 $325,518 - $482,780	23,900 Added 120.71%	43,700 $759,000
Q2 2023 Aug 11, 2023	BUY	$10.44 - $16.48 $206,712 - $326,304	19,800 New	19,800 $278,000
Q4 2022 Feb 14, 2023	SELL	$11.42 - $17.05 $994,682 - $1.49 Million	-87,100 Reduced 81.48%	19,800 $296,000
Q3 2022 Nov 14, 2022	BUY	$9.76 - $13.41 $391,376 - $537,741	40,100 Added 60.03%	106,900 $1.37 Million
Q2 2022 Aug 15, 2022	BUY	$7.6 - $11.41 $319,200 - $479,220	42,000 Added 169.35%	66,800 $647,000
Q1 2022 May 16, 2022	SELL	$9.3 - $12.37 $502,200 - $667,980	-54,000 Reduced 68.53%	24,800 $247,000
Q4 2021 Feb 14, 2022	SELL	$10.39 - $15.15 $117,407 - $171,195	-11,300 Reduced 12.54%	78,800 $927,000
Q3 2021 Nov 15, 2021	SELL	$11.39 - $16.23 $179,962 - $256,434	-15,800 Reduced 14.92%	90,100 $1.03 Million
Q2 2021 Aug 11, 2021	BUY	$13.22 - $19.09 $497,072 - $717,784	37,600 Added 55.05%	105,900 $1.48 Million
Q1 2021 May 17, 2021	SELL	$16.68 - $23.97 $70,056 - $100,674	-4,200 Reduced 5.79%	68,300 $1.26 Million
Q4 2020 Feb 16, 2021	BUY	$14.8 - $21.15 $843,600 - $1.21 Million	57,000 Added 367.74%	72,500 $1.28 Million
Q3 2020 Nov 16, 2020	SELL	$15.21 - $25.53 $215,982 - $362,526	-14,200 Reduced 47.81%	15,500 $237,000
Q2 2020 Aug 14, 2020	BUY	$15.08 - $26.0 $447,876 - $772,200	29,700 New	29,700 $757,000

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $698M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.